22May 2022
Canagliflozin and Atrial Fibrillation in Type 2 Diabetes Mellitus: A secondary analysis from the CANVAS Program and CREDENCE trials and meta‐analysis

Canagliflozin and Atrial Fibrillation in Type 2 Diabetes Mellitus: A secondary analysis from the CANVAS Program and CREDENCE trials and meta‐analysis

The effect of sodium‐glucose co‐transporter two inhibitors on atrial fibrillation/flutter (AF/AFL) is unclear. The study assessed the effects of canagliflozin on the incidence of AF/AFL and other key cardiorenal outcomes in a pooled analysis of the CANVAS and CREDENCE trials. Overall, a significant effect of canagliflozin on the incidence of AF/AFL events could not be shown; however, a possible reduction in AF/AFL events in those with no prior history requires further investigation. Meta‐analysis suggests SGLT2 inhibition reduces AF/AFL incidence.

  • #endo-diabetology

Like

Save

Share